Phase 1 study of zerlasiran in participants with elevated Lp(a) levels (APOLLO, NCT04606602, Completed)

Evaluation of the efficacy, safety and tolerability of zerlasiran (SLN360) in adults with elevated Lp(a) at high risk of atherosclerotic cardiovascular disease (ASCVD) events

Phase 1 study of zerlasiran in participants with elevated Lp(a) levels (APOLLO, NCT04606602, Completed)

Please login or create a FREE account to view this content

Educational Partners and Supporters